Stockreport

AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates [Yahoo! Finance]

AbCellera Biologics Inc. - Common Shares  (ABCL) 
PDF It definitely looks like a negative result overall with revenues falling 19% short of analyst estimates at US$6.5m. Statutory losses were US$0.17 per share, 31% bigger t [Read more]